glp-1 agonists for type 2 diabetes receptor and beyond. Part 1: benefits in New Developments in Pharmacological Treatment
Description
Provider model determines how you access the medication
Among lean tissues, loss of liver mass exceeds change in muscle mass
San Martn A, Du P, Dikalova A, Lassgue B, Aleman M, Gngora MC, et al
The growth is primarily driven by increasing awareness of diabetes and obesity, coupled with rising healthcare investments
[DOI] [PubMed] [Google Scholar] 91.Lu X, Xu C, Dong J, Zuo S, Zhang H, Jiang C, et al
